Trials / No Longer Available
No Longer AvailableNCT01206504
Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- MacroGenics · Industry
- Sex
- All
- Age
- 8 Years
- Healthy volunteers
- —
Summary
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
Detailed description
The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MGAWN1 | Humanized monoclonal to West Nile virus. Dose=30mg/kg |
Timeline
- First posted
- 2010-09-22
- Last updated
- 2022-02-22
Source: ClinicalTrials.gov record NCT01206504. Inclusion in this directory is not an endorsement.